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Introduction
Developing disease modifying treatments for neurode-
generative disease and stroke has proved remarkably dif-
ficult. It may be that current structures in the
pharmaceutical industry encourage early clinical trials
designed on the basis of exciting but incomplete precli-
nical data in order to protect competitive advantage. An
overly generous reading of animal data may lead to
underpowered clinical trials testing treatments at inap-
propriate time points and at ineffective (but side-effect
free) doses. Trials based on a systematic analysis of ani-
mal data may have a better prospect of success. Here,
we report such an analysis of interventions tested in
transgenic models of Alzheimer’s disease (AD).
Materials and methods
(1) Electronic searching of three online databases to
identify publications reporting the use of interventions
in transgenic models of AD where outcome was
reported as behavioural (probe phase of the Morris
water maze (MWM)) or histological (changes in immu-
nohistochemically stained plaque burden) end-points.
(2) DerSimonian and Laird random effects meta-analysis
and stratified meta-analysis.
Results
We identified 428 publications testing 353 interventions
across 55 different transgenic models of AD. Study qual-
ity was low; 16% of papers reported random allocation
to group, 22% reported a blinded assessment of outcome
and no publications reported a sample size calculation.
Blinded assessment of outcome was associated with
lower effect sizes for results from the probe phase of the
MWM. Longer durations between treatment onset and
outcome assessment for plaque burden, and younger
ages at assessment of behavioural outcome were each
associated with lower effect sizes.
Conclusions
Both study quality and study design characteristics
appear to impact observed effect sizes. Study quality was
low, and this was associated with larger estimates of
treatment effects when a behavioural outcome was mea-
sured. Improvement in behavioural outcome (which
may be influenced by effects on underlying pathophy-
siology or by effects on performance in the face of a
fixed deficit) was larger in older animals, but improve-
ment in histological outcomes was smaller with longer
intervals between treatment onset and outcome
assessment.
These findings highlight the importance of a detailed
and systematic analysis of animal data before embarking
on clinical trial. Specifically, if data from animal studies
are to be invoked in support of a trial protocol investi-
gators should be able to demonstrate that such data are
largely free from bias, and that the treatment has shown
efficacy under the circumstances (for instance the stage
of disease) in which it is proposed that it be tested.
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